Search alternatives:
we decrease » _ decrease (Expand Search), nn decrease (Expand Search), teer decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
c decrease » c decreased (Expand Search), _ decrease (Expand Search), rc decreased (Expand Search)
we decrease » _ decrease (Expand Search), nn decrease (Expand Search), teer decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
c decrease » c decreased (Expand Search), _ decrease (Expand Search), rc decreased (Expand Search)
-
11881
-
11882
NADPH oxidation and H<sub>2</sub>O<sub>2</sub> production by Bs3 and Bs3<sub>S211A</sub>.
Published 2021“…<p>A) Buffer containing 100 μM NADPH was mixed with 0.2 μM Bs3 or Bs3<sub>S211A</sub> and incubated at 25°C. …”
-
11883
-
11884
-
11885
Effects of Cyr61 and Wnt5a on regenerating vasculature and musculature.
Published 2015“…At both 4 and 10 weeks, Cyr61KD demonstrated significantly decreased vasculature as compared to Cyr61OX. Data shown as means ± SEM; ***P<0.001 for Cyr61KD vs Cyr61OX. …”
-
11886
-
11887
-
11888
Increased expression of AQP4 protein after hypoglycemia/recovery and decreased expression of tight junction proteins.
Published 2014“…C. Representative picture revealed the decrease of ZO-1 after hypoglycemia. …”
-
11889
-
11890
-
11891
-
11892
-
11893
-
11894
-
11895
-
11896
-
11897
Ophthalmic administration of CXCR3 antagonist decreases intraocular pressure in a rat model of ocular hypertension.
Published 2012“…<i>(B)</i> When the antagonist is administrated twice, intraocular pressure remains low during 6 weeks (n = 10 each); the black arrow indicates the period of retinal and visual <i>in vivo</i> testing presented in <i>Fig. 6A,B</i>. <i>(C)</i> Dose-dependent effect of two administrations of CXCR3 antagonist on intraocular pressure as tested two weeks after the treatment (n = 5 each). * <i>P</i><0.05, ** <i>P</i><0.01. …”
-
11898
-
11899
-
11900